MedPath

Natesto

These highlights do not include all the information needed to use NATESTO safely and effectively. See full prescribing information for NATESTO. Natesto (testosterone) nasal gel CIII Initial U.S. Approval: 1953

Approved
Approval ID

dea6bed1-eaca-11e3-ac10-0800200c9a66

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 19, 2022

Manufacturers
FDA

Acerus Pharmaceuticals Corporation

DUNS: 243912362

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

testosterone

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code42667-5511
Application NumberNDA205488
Product Classification
M
Marketing Category
C73594
G
Generic Name
testosterone
Product Specifications
Route of AdministrationNASAL
Effective DateDecember 19, 2022
FDA Product Classification

INGREDIENTS (4)

SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
APRICOT KERNEL OILInactive
Code: 54JB35T06A
Classification: IACT
CASTOR OILInactive
Code: D5340Y2I9G
Classification: IACT
TESTOSTERONEActive
Quantity: 5.5 mg in 0.122 g
Code: 3XMK78S47O
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.